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Abstract 
Background 
Rapid diagnostic tests (RDTs) for detection of Plasmodium falciparum infection that target P. 
falciparum histidine-rich protein 2 (PfHRP2), a protein that circulates in the blood of patients 
infected with this species of malaria, are widely used to guide case management. 
Understanding determinants of PfHRP2 availability in circulation is therefore essential to 
understanding the performance of PfHRP2-detecting RDTs. 
Methods 
The possibility that pre-formed host anti-PfHRP2 antibodies may block target antigen 
detection, thereby causing false negative test results was investigated in this study. 
Results 
Anti-PfHRP2 antibodies were detected in 19/75 (25%) of plasma samples collected from 
patients with acute malaria from Cambodia, Nigeria and the Philippines, as well as in 3/28 
(10.7%) asymptomatic Solomon Islands residents. Pre-incubation of plasma samples from 
subjects with high-titre anti-PfHRP2 antibodies with soluble PfHRP2 blocked the detection 
of the target antigen on two of the three brands of RDTs tested, leading to false negative 
results. Pre-incubation of the plasma with intact parasitized erythrocytes resulted in a 
reduction of band intensity at the highest parasite density, and a reduction of lower detection 
threshold by ten-fold on all three brands of RDTs tested. 
Conclusions 
These observations indicate possible reduced sensitivity for diagnosis of P. falciparum 
malaria using PfHRP2-detecting RDTs among people with high levels of specific antibodies 
and low density infection, as well as possible interference with tests configured to detect 
soluble PfHRP2 in saliva or urine samples. Further investigations are required to assess the 
impact of pre-formed anti-PfHRP2 antibodies on RDT performance in different transmission 
settings. 
Background 
Malaria rapid diagnostic tests (RDTs) are lateral-flow devices that use antibodies to capture 
and detect parasite proteins by immunochromatography. They have similar sensitivity to light 
microscopy, are easy to use, do not require sophisticated equipment or electricity, and usually 
produce results within 20 minutes. They are recommended by the World Health Organization 
(WHO) as point-of-care diagnostic tools [1] as they provide a parasite-based diagnostic 
alternative to conventional light microscopy. RDTs are playing an increasingly important role 
in malaria case management, particularly in areas where good-quality microscopy is not 
available, with approximately 205 million used globally in 2012 [2]. Indeed, the advent of 
RDTs has made possible the recent update of WHO guidelines for management of malaria 
requiring a parasitological diagnosis in all cases [1]. 
Currently, over 150 malaria RDT brands are commercially available. All utilize antibodies to 
detect one or more of three parasite proteins: Plasmodium falciparum histidine-rich protein 2 
(PfHRP2) unique to P. falciparum, plasmodium lactate dehydrogenase (pLDH) and aldolase, 
the latter two being targets for infection with both P. falciparum and non-P. falciparum 
species. While malaria RDTs have been reported to have detection sensitivity comparable to 
that of thick film microscopy, their performance can vary. Although most reports of 
imperfect sensitivity are at relatively low parasite densities [3-7], false negative results at 
relatively high parasite densities have also been reported [8,9]. Possible explanations for 
imperfect sensitivity at high parasite density include deletion of the pfhrp2 gene [10], varying 
quantity of proteins produced by different parasites [11], the prozone effect [12,13], the 
performance characteristics of the capture and detection antibodies in the kit, including their 
thermal stability [14,15], as well as manufacture quality. 
With respect to quality of manufacture, product testing and lot testing carried out by WHO 
and Foundation for Innovative New Diagnostics (FIND) have demonstrated significant 
variation in performance between different products in detecting diluted field parasites [16]. 
These test results provide explanation for poor performance of some RDTs in the field, 
particularly in detecting moderate and low parasite densities. 
A factor that has not been systematically investigated is the effect of antibodies specific for 
the parasite target antigens that have been generated against these antigens by previous and/or 
current malaria infections. Such antibodies could bind these circulating antigens and form 
immune complexes whilst in circulation or when a blood sample is lysed on an RDT, thereby 
interfering with the binding of antigen to antibodies on the RDT test lines. It is well 
recognized that many proteins released by the malaria parasite during blood stage infection, 
including PfHRP2 are immunogenic and generate an antibody response. PfHRP2 
accumulates in the parasite cytosol, and within the cytosol of infected red cells [17]. It has 
been reported to be both released by infected red cells into the blood, as well as following red 
cell rupture at schizogony [18]. A factor that may favour development of anti-PfHRP2 
antibodies is the relatively long half-life of PfHRP2, compared to other parasite proteins such 
as LDH, with reports that PfHRP2 can circulate for two to four weeks after cure of infection 
[19-21]. 
Biswas and colleagues reported a longitudinal follow-up of PfHRP2 antigenaemia and 
antibody responses in a group of 45 blood smear-positive malaria subjects with P. falciparum 
[22]. They observed that the titre of anti-PfHRP2 antibody gradually rose over the 28 days of 
follow-up. Three of the 45 samples were RDT test negative at baseline. All three had 
significantly lower PfHRP2 antigenaemia and higher titres of anti-HRP2 antibodies compared 
to the 42 RDT-positive samples. This work supports the hypothesis that some malaria-
infected individuals may test PfHRP2 negative because all available PfHRP2 is complexed 
with pre-formed host antibody, and therefore is unavailable for binding with signal antibody 
on an RDT. 
In this study the sero-epidemiology of anti-PfHRP2 antibodies in malaria-endemic 
populations was investigated and the effect of pre-formed antibodies on RDT performance 
was explored. The prevalence and titre of anti-PfHRP2 antibodies in a high transmission area 
of Solomon Islands was investigated, as well as in patients with acute P. falciparum malaria 
in Cambodia, Nigeria and the Philippines. The potential for these antibodies to interfere with 
the performance of RDTs using both recombinant PfHRP2 and cultured parasites was also 
investigated. 
Methods 
Cloning, expression and purification of recombinant PfHRP2 (rPfHRP2) 
Pfhrp2 genes originating from P. falciparum isolate FCQ79 was cloned into the pET8c 
expression vector (Novagen), expressed in Escherichia coli BL21(DE3) LysS cells and 
purified using His-trap Ni-IDA column (GE Healthcare) followed by Superdex 75 10/300 
column (GE Healthcare) (Lee et al., unpublished). 
Determination of rPfHRP2 concentration 
The concentrations of the purified rPfHRP2 were determined using the Biruet assay [23]. 
Briefly, a working reagent was prepared by mixing an equal volume of stock reagent (5% 
sodium citrate, 3% sodium carbonate and 0.5% copper sulphate) with 150 mM NaOH. In 
each well, 40 µl of rPfHRP2 sample was mixed with 160 µl of working reagent in triplicate 
and incubated at room temperature for 25 min. The absorbance of each well was read at 540 
nm and sample concentrations were determined from the standard curve of bovine serum 
albumin (BSA). 
Collection of human plasma 
A total of 121 plasma samples were collected from malaria-endemic regions of four countries 
at different times. Some were collected as part of the parasite collection for the Specimen 
Bank used in the WHO Product Testing for malaria RDTs [24,25]. Samples from acute 
malaria patients (symptomatic and microscopy positive) were collected at time of 
presentation from Cambodia (KH, n = 15), Nigeria (NG, n = 23) and the Philippines (PH, 
n = 37) by Pasteur Institute of Cambodia, University of Lagos and Research Institute for 
Tropical Medicine, the Philippines [24,25]. An additional ten and eight samples were 
collected from microscopy-negative subjects in Nigeria and the Philippines (uninfected 
endemic controls), respectively. The collection and use of the samples was approved by the 
ethics committees of the collection institutions. Methods used for blood collection, parasite 
speciation and quantitation were described in detail in a WHO Methods Manual [26]. Plasma 
was separated from each patient blood and stored at −20°C. A total of 28 plasma samples 
were collected in 1987 [27] in Solomon Islands (SB) with informed consent from 
asymptomatic villagers (13–66 years old) living in Guadalcanal, Solomon Islands [27]. 
Eleven of these villagers were microscopy positive for P. falciparum with low densities while 
the remaining 17 villagers were microscopy negative at the time of collection. All plasma 
samples were stored at −80°C. Plasma samples were also collected from six Brisbane 
residents who had no exposure to Plasmodium infection for use as non-exposed negative 
controls. 
Patient blood sample collection was coordinated by WHO, TDR and FIND and conducted by 
investigators and institutions within the WHO-FIND Malaria RDT Quality Assurance 
Programme. 
ELISA determination of the level of anti-PfHRP2 antibodies 
Purified rPfHRP2 (50 ng/well) was coated on flat-bottomed, 96-well microtitre plates (Nunc, 
Denmark) at 4°C overnight or 37°C for two hours. Plates were blocked with 1% skim milk at 
37°C for one hour. Plasma samples were diluted to 1:200, added in duplicate at 50 µL/well 
and incubated at 37°C for one hour. Plates were washed five times with wash buffer and air-
dried. Anti-human IgG conjugated with horseradish peroxidase (Sigma) was diluted 1:5,000 
and added into the wells (50 µL/well). Plates were incubated for one hour at 37°C and then 
washed five times. OPD substrate buffer (Sigma Aldrich) was added to each well (100 
µL/well), and incubated in the dark for 20 minutes at room temperature. Absorbance was read 
at 450 nm using a microplate reader (VeraMax, Molecular Devices, USA). 
To establish relative antibody concentrations against rPfHRP2, five human plasma that 
contained high anti-PfHRP2 antibody levels were identified and pooled for use as a reference 
standard. This standard plasma pool was two-fold diluted in PBS from 1:100 to 1:1,600, and 
applied, in duplicate, to each assay plate. ELISA units were arbitrarily assigned to each 
dilution. Two wells that contained PBS were used as a negative control and were also used to 
blank all samples and standard plasma. 
The OD450 readings of the serial dilutions of the standard plasma pool were plotted on a four-
parameter hyperbolic curve (SOFTmax Pro ver 3.1; Molecular Devices). If R2 was less than 
0.9, the assay was deemed invalid and was repeated. ELISA units in test plasma were 
interpolated from their mean OD450 values from the standard curve. The positive threshold 
(13.1) was defined as two standard deviations above the mean ELISA units (8.4) of a pool of 
six human plasma samples from individuals never exposed to malaria. 
Determining the quantity of circulating PfHRP2 antigen in plasma using 
ELISA 
A commercially available SD Malaria Antigen Pf ELISA kit (Standard Diagnostics Inc, 
Korea) was used to detect PfHRP2 antigen in human plasma. The assay was performed 
following manufacturer’s instructions, with the exception of the initial lysis and conjugation 
step. Briefly, 50 µL of each sample were incubated with 75 µL of lysis buffer, containing 
horseradish peroxidase enzyme conjugate, at 37°C for 15–30 minutes. A 100-µL volume of 
the mixture was then transferred to the supplier’s PfHRP2-coated microtitre plate, and 
incubated at 37°C for 90 minutes. Plates were washed six times with wash buffer before 
substrate was added. The reaction was stopped with stopping solution after incubation at 
room temperature for 30 minutes, and plates were immediately read on a microplate reader 
(VeraMax, Molecular Devices) at 450 nm with a reference of 620 nm. 
To quantify the plasma PfHRP2 level, a PfHRP2 antigen standard concentration curve was 
established using a set of doubling dilutions of a P. falciparum 3D7 culture supernatant. The 
concentration of PfHRP2 in the culture supernatant (ng/mL) was determined by comparing its 
OD450 value to a known protein concentration standard curve that was prepared by serial 
dilutions of rPfHRP2 (FCQ79). These standard dilutions were used as a reference standard 
for each assay plate. The PfHRP2 concentration (ng/mL) in each plasma sample was 
determined by reference its OD450 value to the standard curve assayed on the same plate. The 
limit of detection of this ELISA was determined to be 0.5 ng/mL. 
Measuring the blocking effects of plasma on the detection of soluble PfHRP2 
using ELISAs and RDTs 
Two high-titre plasma samples from Solomon Islands, S14 and S53, were identified and used 
as sources of anti-PfHRP2 antibody; culture supernatant from an in vitro culture of the P. 
falciparum strain 3D7 was used as source of parasite PfHRP2 antigen. The culture 
supernatant was subject to two-fold doubling dilutions with RPMI media from 1:2 to 1:126; 
50 µL of each dilution was mixed with 50 µL of plasma, undiluted or diluted 1:5. Culture 
supernatant was used as the ‘no plasma’ control; pooled plasma from non-exposed negative 
controls was used as the negative plasma control. Antibody-antigen mixtures were incubated 
at 37°C for one hour, transferred to the SD Malaria Antigen Pf ELISA kit, and processed as 
described above. The OD450 in mixtures with and without human plasma was compared. 
Concurrently, 5 µl of each mixture was transferred onto three different malaria RDTs: ICT 
Malaria Combo Cassette Test (ML02, ICT Diagnostics, South Africa), First Response 
Malaria Antigen pLDH/HRP2 Combo (116FRC30, Premier Medical Corp, India) and SD 
Malaria Antigen Pf (05FK50, Standard Diagnostics, Korea). Results were read by two 
independent readers and recorded as levels 0–4 based on the test band intensity following the 
WHO colour chart [24]. 
Investigating the blocking effects on ELISA and RDT detection of 
Plasmodium falciparum in tissue culture using plasma containing anti-PfHRP2 
antibodies 
Three culture-adapted P. falciparum lines originating from Solomon Islands (S55, SJ44 and 
SJ15) were cultured in vitro using standard culture conditions [28]. Parasite cultures were 
repeatedly synchronized using 5% sorbitol [29], then maintained and harvested when 
parasitaemia reached 2% with majority at ring stage. An aliquot of the harvested parasites 
was concentrated to 50% haematocrit by centrifuging and discarding excess supernatant. A 
second aliquot of the culture was pelleted, washed and resuspended in fresh media to a 50% 
haematocrit. Both aliquots were diluted using normal human blood maintaining a 50% 
haematocrit to parasite densities of 100,000, 30,000, 10,000, 3,000, 1,000, 300, 100, and 30 
parasites/µL. An aliquot of each dilution was incubated with the immune human plasma (S14 
or S53) or negative control plasma for one hour at room temperature. These samples were 
then tested on a RDT as described above. 
Statistical analysis 
The ages, parasite densities and PfHPR2 antigen levels in the patient samples were compared 
between countries of origin using the Kruskal Wallis test. Proportions were compared 
between countries using either Fisher’s exact test (for comparison of two categories) or Chi-
square Test (>two categories). Correlation between parasitaemia and antibody or antigen 
level was assessed using Spearman’s Rank Correlation. 
Results 
Demographic and parasitologic characteristics of the subjects from whom the 
plasma samples were collected 
Blood samples were collected from patients with acute malaria in Cambodia (n = 15), Nigeria 
(n = 23) and the Philippines (n = 37). The age of these individuals and levels of parasitaemia 
are presented in Table 1 and Additional file 1. There were no significant differences in the 
ages of the patients recruited at each site (P > 0.50). The geometric mean parasite density of 
samples differed by country of origin (P < 0.001); densities from Nigeria (18,528/µL, 95% 
CI: 12,686-27,059/µL) and Cambodia (20,940/µL, 95% CI: 9,766-44,897/µL) were not 
significantly different (P > 0.05), but were significantly higher than in samples from the 
Philippines (1,767/µL, 95% CI: 811–3,850/µL; P < 0.01). The Solomon Islands samples were 
collected in 1987 from a high transmission area. All subjects were asymptomatic at the time 
of collection. Eleven of the 28 individuals were microscopy-positive for P. falciparum, with 
low-density infection (exact parasite density was not available). The remaining 17 
individuals, nine of whom reported a history of malaria were blood smear negative at the time 
of collection. 
  
Table 1 Demographics and parasitaemia of the plasma samples 
Sample type Country n Age Parasitemia 
Median (Range) Geometric mean (Range) 
Acute patients 
(symptomatic & 
microscopy + ve) 
Cambodia 15 21 (8–51) 20,940 (2,005-195,665) 
Nigeria 23 23 (9–37) 18,528 (5,118-142,696) 
Philippines 37 19 (4–71) 1,767 (30–79,821) 
Asymptomatic 
(microscopy + ve or –ve) 
Solomon 
Islands 
28 *29 (13–66) 11 were microscopy positive for 
P. falciparum with low densities 
Uninfected endemic controls Nigeria 10 Unknown  N/A 
Philippines 8 28 (7–76) N/A 
Non-exposed control Brisbane 6 Unknown  N/A 
* Calculated based on information available from 17 subjects. An additional five subjects were adults, and six 
subjects had unknown age. 
Anti-PfHRP2 antibody levels in plasma samples 
Plasma samples were analysed for anti-rPfHRP2 antibody levels using ELISA. The mean 
ELISA unit among the non-exposed negative controls was 8.4 ± 2.3, while the corresponding 
level for the ten parasite-negative Nigerian samples was 2.7 ± 1.1. Nineteen of the 75 patients 
with acute malaria (25.3%) had anti-PfHRP2 antibody levels above the cut-off value (13.0 
units), with the prevalence of antibodies in samples from Cambodia, Nigeria and the 
Philippines not being significantly different (20.0, 34.7 and 21.6%, respectively; P > 0.40). 
The prevalence of anti-PfHRP2 antibodies among the asymptomatic Solomon Islanders was 
lower at 10.7%, although not significantly different from prevalence in patients with acute 
malaria (P > 0.15). 
Levels of anti-PfHRP2 antibodies are shown in Figure 1 (with raw Optical Density results 
shown in Additional file 2). The majority of the antibody-positive samples had antibody 
levels between one to three-fold higher than the cut-off value, while two plasma samples had 
antibody levels that were five-fold (NG02F22) and 16.7-fold (SB014) higher than the cut-off 
value. Overall there was a positive correlation between antibody level and age of infected 
subjects. However, this was not statistically significant for the combined set of parasite 
positive samples (r = 0.20, P = 0.08, n = 79), nor within individual countries (KH: r = 0.23, 
P = 0.39; PH: r = 0.05, P = 0.75; NG: r = 0.16, P = 0.47, SB (Pf positive): r = −0.32, 
P = 0.50). There was also no significant correlation between parasitaemia and antibody level 
in the symptomatic patient samples (r = −0.06, P = 0.62.) 
Figure 1 Anti-PfHRP2 antibody levels in plasma samples. Levels of PfHRP2-specific 
antibodies in the plasma of subjects were measured by ELISA. Cut-off is shown by the dotted 
line, and Error Bars represent 95% Confidence Intervals. Country of origin is represented 
using ISO 3166 country code: Cambodia (KH), Nigeria (NG), the Philippines (PH), and 
Solomon Islands (SB). BNE represents Brisbane. Samples from subjects who were 
microscopy negative for P. falciparum are shown as Neg. 
PfHRP2 antigen levels in plasma samples 
PfHRP2 antigen was detected by ELISA in 100, 91.3 and 62.2% plasma of patients with 
symptomatic malaria in Cambodia, Nigeria and the Philippines, respectively, while only 6/28 
(21.43%) of plasma from asymptomatic subjects from the Solomon Islands had detectable 
PfHRP2 antigen (Table 2). Five of these six subjects were positive for P. falciparum by 
microscopy. None of the parasite-negative subjects from Nigeria (n = 10), the Philippines 
(n = 8) or Brisbane (n = 6) had detectable PfHRP2 in their plasma samples (Table 2). 
Table 2 Number and proportion of samples positive for PfHRP2 antigen and anti-
PfHRP2 antibody by ELISA 
Sample type Country n Antigen Antibody 
No (%) No (%) 
Acute patients (symptomatic & microscopy + ve) Cambodia 15 14* (100)* 3 (20.0) 
 Nigeria 23 21 (91.3) 8 (34.7) 
 Philippines 37 23 (62.2) 8 (21.6) 
 Sub-total 75 57 (76.0) 19 (25.3) 
Asymptomatic (microscopy + ve or –ve) Solomon Islands 28 6 (21.4) 3 (10.7) 
Uninfected endemic controls Nigeria 10 0 0 0 0 
 Philippines 8 0 0 2 (25) 
Non-exposed controls Brisbane 6 0 0 0 0 
*Antigen measured for 14 samples. 
The level of PfHRP2 antigen present in individual plasma samples is shown in Figure 2. For 
samples from symptomatic patients with detectable antigen, there was no significant 
difference in the distribution of antigen level according to country of origin (P = 0.27). The 
mean antigen levels were 9.45 ng/mL (95% CI: 7.42-11.49 ng/mL), 11.62 ng/mL (95% CI: 
9.14-14.11 ng/mL) and 11.14 ng/mL (95% CI: 6.60-15.69 ng/mL), for Cambodia, Nigeria 
and the Philippines, respectively. The antigen levels among the Solomon Islands 
asymptomatic subjects (for which antigen was detected) were significantly lower 
(mean =0.70 ng/mL, 95% CI: −0.09-1.48 ng/mL) than for the symptomatic patients in 
Cambodia, Nigeria and the Philippines (P < 0.01). There was a significant positive correlation 
between parasite density as determined by blood smear and plasma PfHRP2 level for the 
symptomatic patient samples (r = 0.45, P < 0.0001, n = 74, Figure 3). 
Figure 2 PfHRP2 antigen levels in plasma samples. PfHRP2 antigen levels were measured 
in a commercial ELISA test (Standard Diagnostics, Korea). Country of origin is represented 
using ISO 3166 country code: Cambodia (KH), Nigeria (NG), the Philippines (PH), and 
Solomon Islands (SB). Shown are the results from subjects who tested positive. Error Bars 
represent SEM. 
Figure 3 Relationship between parasitaemia and plasma PfHRP2 level in samples from 
symptomatic patients. 
Correlation between anti-PfHRP2 antibody levels and levels of PfHRP2 
antigen 
Data on anti-PfHRP2 antibody level and PfHRP2 antigen level were available for 74 samples. 
Of the 18 samples from patients with acute malaria who had anti-PfHRP2 antibodies above 
the cut-off, 14 (77%) were PfFHRP2 antigenaemic. There was no significant association 
between antibody presence and presence of antigen (P > 0.90). Logistic regression indicated 
that antigen level was not a significant factor for predicting the presence of anti-PfHRP2 
antibody (P = 0.44). Although samples with high antigen levels tended to have lower 
antibody levels, and samples with the highest antibody level tended to have low antigen 
levels (Figure 4), this relationship was not statistically significant. 
Figure 4 Relationship between plasma anti-PfHRP2 antibody and plasma PfHRP2 
antigen level. Country of origin is represented using ISO 3166 country code: Cambodia 
(KH), Nigeria (NG), the Philippines (PH), and Solomon Islands (SB). Ab represents 
antibody. PF + and PF – represents microscopy positive and negative, respectively, for P. 
falciparum. 
The blocking effect of plasma-containing anti-PfHRP2 antibodies on the 
detection of soluble PfHRP2 and parasitized erythrocytes by RDTs 
When two plasma samples with high-titre anti-PfHRP2 antibody were pre-incubated with 
serial dilutions of culture supernatant from an in vitro culture of the P. falciparum, a 
significant reduction in OD values in the HRP2 antigen-capture ELISA was observed at all 
antigen dilutions tested. Figure 5 demonstrates the effect of a serum from one of these two 
subjects (S14). The same effect was also observed when the plasma was diluted five-fold, 
except at the highest antigen concentration tested (55.5 ng/mL), or when undiluted plasma 
from another subject with high-titre antibody (S53) was used. The plasma pool from Brisbane 
subjects had no or minimal effect on the detection of antigens by ELISA. 
Figure 5 Anti-PfHRP2 antibody inhibits ELISA detection of soluble PfHRP2 antigen. 
Culture supernatant from an in vitro culture of P. falciparum was pre–incubated in serial 
dilution with a plasma sample with high-titre anti-PfHRP2 antibody and tested in a 
commercial HRP2 antigen-capture ELISA. Four-fold dilutions are shown. 
When the pre-mixed plasma-antigen mixtures were tested on three commercially available 
malaria RDTs, complete blocking of the detection was observed with two brands of RDT 
(First Response and SD) resulting in negative RDT results (Table 3). The blocking effect 
diminished when the plasma was diluted five-fold. Interestingly, the performance of the third 
brand of RDT (ICT combo) was not as markedly affected by pre-incubation with plasma with 
high-titre, anti-PfHRP2 antibody, and tested positive in all situations (Table 3). 
Table 3 The effect of anti-PfHRP2 antibodies on the detection of soluble PfHRP2 by 
RDTs 
Culture 
supernatant 
First response SD ICT 
No 
Ab 
Normal 
plasma 
S14 S14 
1:5 
No 
Ab 
Normal 
plasma 
S14 S14 
1:5 
No 
Ab 
Normal 
plasma 
S14 S14 
1:5 
Undiluted 4 4 0 1 4 4 0 2 4 4 4 4 
1:2 4 4 0 0 4 4 0 0 4 3 3 2 
1:4 4 2 0 0 3 3 0 0 3 2 1 1 
1:8 1 1 0 0 1 2 0 0 2 1 1 1 
1:16 1 1 0 0 1 1 0 0 1 1 1 1 
1:32 0 0 0 0 0 0 0 0 1 0 0 0 
1:64 0 0 0 0 0 0 0 0 1 0 0 0 
1:128 0 0 0 0 0 0 0 0 1 0 0 0 
Suspensions of three separate P. falciparum lines were tested at seven different dilutions 
(100,000 P/µL to 30 P/µL) by incubating each with either a human plasma sample of high 
anti-PfHRP2 antibody (S14) or normal human plasma for one hour at room temperature, then 
tested in the antigen ELISA and the three RDTs named above. When the three brands of RDT 
were tested, a varying level of blocking effect was observed for all three brands tested against 
the N70 parasite line that originated from the Solomon Islands (Figure 6). The effect was 
apparent as a reduction of signal intensity from four to three or two at 100,000 P/µl and/or a 
reduction of lower detection threshold by ten-fold (from 300 to 3,000 P/µl, or from 1,000 to 
10,000/µl). A similar blocking effect was also observed when the three RDTs were tested on 
S55 line (Additional file 3). However, a markedly lesser blocking effect was seen when 
RDTs were tested on SJ15 line (Additional file 4). 
Figure 6 Anti-PfHRP2 antibody impairs the ability of three PfHRP2-detecting RDTs to 
detect cultured P. falciparum. Three brands of RDT (SD, ICT and First Response) were 
tested with P. falciparum-parasitized red cells pre-incubated with normal plasma (NP) or 
plasma from a subject with high titre anti-PfHRP2 antibody level (S14). Blood was serially 
diluted using normal human blood maintaining a 50% haematocrit to parasite densities of 
100,000, 30,000, 10,000, 3,000, 1,000, 300, 100, and 30 parasites/µL (1–8). The experiment 
was undertaken before (A) and after (B) the blood was washed to remove any residual 
PfHRP2 present in the culture medium. 
Discussion 
PfHRP2-detecting RDTs are the most important tools for the rapid diagnosis of falciparum 
malaria and their results form the basis for case management decisions. Factors that may 
influence the accuracy and sensitivity of PfHRP2-detecting RDTs therefore need to be 
investigated and their potential impact evaluated. The purpose of this study was to investigate 
the potential for anti-PfHRP2 antibody accumulated in semi-immune individuals, to influence 
the performance of RDTs in detecting blood stage P. falciparum parasites. 
The results of this study indicate that detectable anti-PfHRP2 antibody was present in up to 
35% of patients presenting with P. falciparum infection in three countries from Africa, Asia 
and Oceania, with an overall prevalence of 25%. Anti-PfHRP2 antibody was also detected in 
10.7% of asymptomatic Solomon Islanders, including individuals without parasitaemia 
detected by blood smear, suggesting that they carried pre-formed anti-PfHRP2 antibodies. 
Although antibody levels did not correlate with age or incident parasitaemia among the 
subjects, the highest antibody levels were observed in a Solomon Islander and Nigerian who 
lived in countries with areas of high transmission intensity, compared to subjects from the 
Cambodia and the Philippines where transmission intensity is generally lower. This implies 
that the antibody levels may relate to transmission intensity, i.e. the rate of exposure to 
infections. However, the relatively low prevalence of antibodies in people living in high 
transmission areas of Solomon Islands, the lack of correlation between antibody levels and 
age or parasitaemia suggest that PfHRP2 is likely not highly immunogenic. 
As expected, PfHRP2 antigen was also detected in plasma of most of the patients with acute 
P. falciparum infection from three countries. A subset of these samples (n = 42; 14, 19 and 
nine from Cambodia, Nigeria and the Philippines, respectively) had previously been tested 
positive (100%) for PfHRP2 antigen in the whole blood sample using an in-house ELISA. 
Forty of these 42 plasma samples were also positive for PfHRP2 by ELISA. The negative test 
results for PfHRP2 antigen in the plasma of the two patients in Nigeria who had moderate 
levels of parasitaemia (49,855/µl and 6,815/µl) and detectable antigen in whole blood is 
unexpected and requires further investigation. One possibility is that in early infection the 
levels of free antigen in plasma are below the level of detection, as it is known that the 
majority of PfHRP2 is present within infected red cells and released into plasma when 
infected erythrocytes are destroyed [18]. It is also possible that the PfHRP2 had degraded 
during storage and transport of the two plasma samples. Antibodies to PfHRP2 were present 
in the plasma of the subject with a parasitaemia of 49,855 but not in the other. Thus, antibody 
binding could only explain one case. 
Of note, a significant positive correlation between parasite density and plasma PfHRP2 
antigen level was detected. The level of PfHRP2 in patients in a high transmission area 
(Nigeria) was significantly higher than that in patients from a low transmission area (the 
Philippines). This may be related to differences in the level of acquired immune responses 
between the subjects of these two countries. People living in areas with low transmission 
intensity such as the Philippines, are more likely to have less immunity and present for 
treatment early during an infection. These people would be expected to have lower level of 
PfHRP2 in their plasma than those from Nigeria. It is also possible that this observation is 
due to sampling bias as the study was not designed to systematically answer the question of 
the association between antigenaemia, antibody levels and levels of transmission. 
It is of interest that subjects with high plasma antigen levels tended to have low antibody 
level and vice versa, suggesting antibody-antigen complexes may have been formed in 
patients’ plasma. These immune complexes are expected to not only impact on the prevalence 
and levels of anti-PfHRP2 in the subjects, but more importantly, to block the binding of free-
PfHRP2 by antibodies embedded in malaria RDTs, potentially leading to false negative 
results. This effect has been previously reported in antigen-capture diagnostic tests, for 
example with p24 antigen in HIV [30]. In this setting, harsh methods not readily amenable to 
adaptation to card tests (such as acid [30] or heat [31] dissociation) were required to 
dissociate these immune complexes. In this study the effect of dissociation of immune 
complexes as a means of abrogating this effect was not investigated. Likewise, the 
explanation for one of the tests being less affected was not explored, and remains a priority 
for future study. It is possible however that the single brand of RDT for which a blocking 
effect was not detected may have incorporated a step that would achieve this objective. It also 
remains possible that this blocking effect is caused by a phenomenon other than pre-existing 
antibodies as the role of such antibodies has not been conclusively established in this study. 
In this study the pre-incubation of plasma with high titre antibody (16.7-fold higher than the 
cut-off value) against PfHRP2 with culture supernatant containing soluble PfHRP2 resulted 
in a significant reduction in OD values of ELISA and a false negative reading on two of the 
three RDTs tested. This effect could be titrated out by diluting the plasma 1:5. When the 
same plasma was incubated with cultures containing intact parasitized erythrocytes, a 
reduction in band intensity at the highest parasite density was observed for all three brands of 
RDTs. Importantly, unlike soluble antigens, no false negative RDT results were observed at 
the highest parasite density. However, the lower detection threshold decreased by ten-fold in 
all three brands of RDTs tested on two of the three parasite lines. The relatively weaker 
blocking effect observed in the detection of whole cell compared to soluble antigens is likely 
due to less free PfHRP2 available to form immune complex at the pre-incubation as most of 
PfHRP2 is located within the red cells. The majority of intra-erythrocytic PfHRP2 would 
only be released when blood cells are lysed on RDTs. Even so, a proportion of PfHRP2 was 
able to form immune complex with antibodies in the plasma immediately upon the lysis of 
blood on the RDT, and to reduce signal intensity at highest parasite density, and to reduce the 
lower detection threshold by ten-fold. This is supported by a similar blocking effect observed 
when parasite cultures were washed with fresh media to remove free PfHRP2. 
The findings of this study confirm that people infected with P. falciparum parasites develop 
antibodies against PfHRP2, with some subjects developing very high levels of anti-PfHRP2 
antibody. As a consequence, the detection sensitivity of RDTs on blood samples from 
individuals with such anti-PfHRP2 antibodies can fall by up to ten-fold. This has important 
implications for malaria diagnosis in areas with high transmission where people are often in 
semi- to hyper-immune, and have high-titre antibodies to a broad range of parasite antigens. 
Like the prozone-like effect described elsewhere [12,13], this would limit the ability to rely 
on RDT test line intensity (or an electronic reader) to determine parasite load and severity of 
infection. The antibody-antigen interaction and its potential impact on RDT performance are 
illustrated in Additional file 5. 
The impact of antibody blocking on the detection sensitivity of RDTs will depend on the 
prevalence and the titre of anti-PfHRP2 antibodies. In the relatively small sample sets from 
the Solomon Islands (n = 28) and Nigeria (n = 23), one individual in each group had very 
high antibody titre (>five-fold higher than the cut-off value), and co-incubation of these sera 
had a significant effect on the detection threshold of RDTs. The effect of antibody blocking 
may be increased if saliva [32] or urine [33] are tested for soluble PfHRP2, as levels are 
lower in these biological fluids, and secreted antibody may be present. It is also possible that 
a similar blocking effect may affect the performance of RDTs targeting parasite biomarkers 
other than PfHRP2, such as LDH and aldolase. It should be noted that this is a proof of 
concept study demonstrating that individuals with antibodies against HRP2 can block the 
RDT detection of parasites, and future studies are required to define the minimum level of 
antibodies required to cause a significant blocking effect. 
Conclusion 
Although further studies are required to determine the sero-epidemiology of anti-PfHRP2 
antibodies in areas with different transmission intensities, as well as a more comprehensive 
investigation of this factor as a contributor to false negative tests, these observations indicate 
possible reduced diagnostic sensitivity for diagnosis of P. falciparum malaria using PfHRP2-
detecting RDTs, particularly among people with high levels of specific antibodies and low 
density infection. 
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Additional files 
Additional_file_1 as PDF 
Additional file 1. Parasite densities in subjects with acute Plasmodium falciparum infection. 
Country of origin is represented using ISO 3166 country code: Cambodia (KH), Nigeria 
(NG), the Philippines (PH) and Solomon Islands (SB). Bars represent geometric mean with 
95% CI. 
Additional_file_2 as PDF 
Additional file 2. Optical Density values of PfHRP2-specific antibody levels in the plasma of 
subjects measured by ELISA. Horizontal lines denote the mean OD in each group. Country of 
origin is represented using ISO 3166 country code: Cambodia (KH), Nigeria (NG), the 
Philippines (PH), and Solomon Islands (SB). BNE represents Brisbane. Samples from 
subjects who were microscopy negative for P. falciparum are shown as Neg. 
Additional_file_3 as PDF 
Additional file 3. Anti-PfHRP2 antibody impairs the ability of three PfHRP2-detecting 
RDTs to detect cultured P. falciparum S55. Three brands of RDT (SD, ICT and First 
Response) were tested with P. falciparum-parisitized red cells pre-incubated with normal 
plasma (NP) or plasma from a subject with high titre anti-PfHRP2 antibody level (S14). 
Blood was serially diluted using normal human blood maintaining a 50% haematocrit to 
parasite densities of 100,000, 30,000, 10,000, 3,000, 1,000, 300, 100, and 30 parasites/µL (1-
8). The experiment was undertaken before (A) and after (B) the blood was washed to remove 
any residual PfHRP2 present in the culture medium. 
Additional_file_4 as PDF 
Additional file 4. Anti-PfHRP2 antibody impairs the ability of three PfHRP2-detecting 
RDTs to detect cultured P. falciparum SJ15. Three brands of RDT (SD, ICT and First 
Response) were tested with P. falciparum-parisitized red cells pre-incubated with normal 
plasma (NP) or plasma from a subject with high titre anti-PfHRP2 antibody level (S14). 
Blood was serially diluted using normal human blood maintaining a 50% haematocrit to 
parasite densities of 100,000, 30,000, 10,000, 3,000, 1,000, 300, 100, and 30 parasites/µL (1-
8). The experiment was undertaken before (A) and after (B) the blood was washed to remove 
any residual PfHRP2 present in the culture medium. 
Additional_file_5 as PDF 
Additional file 5. Illustration of interactions between host anti-PfHRP2 antibodies and 
parasite PfHRP2 and their potential impact on RDT performance. 
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